Trial Profile
A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vulva or Anus
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Anal cancer; Cervical cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ABBIMUNE
- 10 Feb 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
- 10 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Jul 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2024.